The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain patients with the blood ...

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

When you have multiple myeloma, infections are something you’ll need to watch out for. The disease and its treatment make infections more likely. If you get an infection, it’s also more likely to get ...

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) For over half a ...

IGD (Institute of Grocery Distribution) has announced a new insight programme called, ‘IGD Futures: GLP‑1’, to help food industry businesses understand, navigate, and capitalise on the impacts of ...

IGD is launching a new insight programme to help food companies navigate the impact of GLP-1 weight-loss medication. The IGD Futures: GLP-1 programme will aim to help food industry businesses ...

Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...

The FDA has accepted Bristol Myers Squibb (BMS)’s New Drug Application (NDA) for iberdomide for relapsed or refractory ...